Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone
In Brief: FCRF Contract Hopefuls Make Oral Presentation; Jane Rowley To Deliver Karnofsky Lecture
Will Latest Report By Rosenberg Stir Up Critics? Some DCT Board Members Defend the Press
“Official Chronology” Of Gall/Montagnier Finding Agreed On; Royalties to Fund AIDS research
Spartanburg CCOP Makes the List
WETA Relents Will Air Documentary
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation